Name (Synonyms) | Correlation | |
---|---|---|
drug2494 | The standard of care Wiki | 1.00 |
drug1853 | Placebo oral tablet Wiki | 0.19 |
drug1086 | Hydroxychloroquine Wiki | 0.10 |
Name (Synonyms) | Correlation | |
---|---|---|
D003141 | Communicable Diseases NIH | 0.09 |
D007239 | Infection NIH | 0.06 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
An Open-label, prospective, randomized, comparative, multiple doses applied in addition to the standard of care treatment of patients with moderate to severe COVID-19 infection
Description: The time of onset of improvement in the patient's clinical condition will be measured following the clinical objective and subjective signs and radiological indicators.
Measure: Time to onset of change in the patient's clinical condition Time: 21 dayDescription: At every examination/evaluation, all AEs, whether noticed by investigators and their associates in the trial, or spontaneously reported by the subjects, or given as answer to direct question, must be evaluated by the investigator and reported on case report forms for AE. AE will be recorded in the e-CRF. Three-degree scale will be used for assessment of AE's severity: mild, moderate, severe.
Measure: Safety and tolerability evaluation - treatment-related adverse events will be assessed by CTCAE Time: 21 dayDescription: To monitor the period of patient's hospitalization
Measure: Length of in-hospital stay Time: 21 dayDescription: To monitor the survival rate during the hospitalization
Measure: Survival rate Time: 21 dayDescription: To monitor the intubation frequency during the hospitalization
Measure: Intubation rate Time: 21 dayDescription: To monitor the levels of proinflammatory markers during the hospitalization (IL-6)
Measure: Proinflammatory markers levels Time: 21 day